Functional Inspiratory Versus Expiratory Muscle Electrical Stimulation on Weaning Outcomes in Mec… (NCT07204821) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Functional Inspiratory Versus Expiratory Muscle Electrical Stimulation on Weaning Outcomes in Mechanically Ventilated Patients
Egypt48 participantsStarted 2026-06-15
Plain-language summary
The Goal of This Clinical Trail is
* To find out the difference in the effect of inspiratory muscle functional electrical stimulation and expiratory muscle functional electrical stimulation on weaning outcomes mechanically ventilated patients.
* To investigate the effect of inspiratory muscle functional electrical stimulation and expiratory muscle functional electrical stimulation on Laboratory investigation (Arterial Blood Gases).
* To investigate the effect of inspiratory muscle functional electrical stimulation and expiratory muscle functional electrical stimulation on Sonar parameters (Diaphragmatic excursion, Diaphragmatic muscle fractional thickness in the end of inspiration and the end of expiration and abdominal muscles wall thickness). To evaluate the effect of inspiratory muscle functional electrical stimulation and expiratory muscle functional electrical stimulation on (ICU length of stay and Spontaneous Breathing Trail (SBT)).
Who can participate
Age range
45 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* All mechanically ventilated patients will be:
* Their ages range from 45 to 65 years.
* Their BMI is from 25-29.9kg/m2.
* Mechanically ventilated for at least 24 hours.
* They all have hypoxemic respiratory failure
* Glasgow coma score (GCS) ranged from 6 to 12.
* Richmond Agitation-Sedation Scale score: -2 to +2
* Patients and their relatives had written informed consent.
Exclusion Criteria:
* Hemodynamically unstable patients.
* Patients with rib fractures.
* Patients with implanted pacemaker.
* Obese (BMI greater than 30 kgm2).
* Tachycardia.
* Uncontrolled hypertension.
* History of neuromuscular disease at admission.
* Spinal injuries.
* Inability to trigger mechanical ventilation
* Pregnancy
* An anticipated stay on the ventilator \<72 h at the time of study
* Patients who cannot attach electrodes due to local skin damage or infection
* Patients with Severe intestinal gas accumulation, structural abnormalities, and other reasons that prevent ultrasound detection of diaphragm movement.
* Congenital myopathies or neuropathies, and contraindications for expiratory muscle FES (cardiac pacemaker, refractory epilepsy, recent (\< 4 weeks) abdominal surgery).
* Patients with unrelieved pneumothorax and restricted diaphragm movement disorders.
* Chest or diaphragm malformation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
pH (arterial blood gas)
Timeframe: Baseline (within 24 hours prior to intervention) and at successful weaning from mechanical ventilation (within 24 hours of extubation).
2
PaO₂ (mmHg, arterial blood gas)
Timeframe: Baseline (within 24 hours prior to intervention) and at successful weaning from mechanical ventilation (within 24 hours of extubation).
3
PaCO₂ (mmHg, arterial blood gas)
Timeframe: Baseline (within 24 hours prior to intervention) and at successful weaning from mechanical ventilation (within 24 hours of extubation).
4
SaO₂ (%)
Timeframe: Baseline (within 24 hours prior to intervention) and at successful weaning from mechanical ventilation (within 24 hours of extubation)
5
HCO₃ (mmol/L, arterial blood gas)
Timeframe: Baseline (within 24 hours prior to intervention) and at successful weaning from mechanical ventilation (within 24 hours of extubation)